Wells Fargo initiated coverage of Relay Therapeutics (RLAY) with an Equal Weight rating and $4 price target The firm likes Relay’s lead program RLY-2608, but thinks upside for shares may prove difficult as Wells sees a lack of near-term catalysts. While shares are cheap, the firm would wait before stepping in.
Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on RLAY:
- Strategic Operational Changes and Financial Stability Bolster Relay Therapeutics’ Buy Rating
- Relay Therapeutics weakness brings buying opportunity, says Barclays
- Relay Therapeutics: Promising Clinical Trials and Strategic Positioning Justify Buy Rating
- Buy Rating for Relay Therapeutics Amid Strategic Clinical Progress and Resource Optimization
- Relay Therapeutics price target lowered to $12 from $21 at Citizens JMP
Looking for a trading platform? Check out TipRanks' Best Online Brokers , and find the ideal broker for your trades.
Report an Issue